Virginia Community College System

Digital Commons @ VCCS
Student Writing

Student Scholarship and Creative Works

Fall 2017

Furosemide: Properties, Alternatives, and the
Medication Approval Process
Heather Brown
Rappahannock Community College

Follow this and additional works at: https://commons.vccs.edu/student_writing
Part of the Chemicals and Drugs Commons, Pharmacy Administration, Policy and Regulation
Commons, and the Therapeutics Commons
Recommended Citation
Brown, Heather, "Furosemide: Properties, Alternatives, and the Medication Approval Process" (2017). Student Writing. 33.
https://commons.vccs.edu/student_writing/33

This Paper is brought to you for free and open access by the Student Scholarship and Creative Works at Digital Commons @ VCCS. It has been
accepted for inclusion in Student Writing by an authorized administrator of Digital Commons @ VCCS. For more information, please contact
tcassidy@vccs.edu.

Furosemide: Properties, Alternatives, and
the Medication Approval Process
Heather Brown
EMS 209-Advanced Pharmacology
Don Knox

Pre-hospital treatment of critical patients is a key factor in determining overall outcomes.
Actions that are completed in the field can vastly improve patient wellness during their hospital
stay and after discharge. However, there is more to treating a patient than simply pushing
medications through an IV in their peripheral vein. Certain medications are indicated for specific
conditions and of these, some work better than others. For edema, the common medication is
furosemide, although this is not the only drug that can treat edema in the pre-hospital or hospital
settings. Thiazides, thiazide-like diuretics, and potassium-sparing diuretics are also useful
treatments and will be discussed later.

Furosemide
Furosemide (Lasix) is a potent loop diuretic that is used to increase urine production to
reduce fluid in the body. It is commonly referred to as a “water pill” or “fluid pill” due to its
effects (Guy, 2011, p201). Loop diuretics are specifically used for edema from heart failure,
hypertension, and as an adjunctive treatment in acute pulmonary edema (Comerford, 2016; Guy,
2011; Levy and Bellou, 2013; Vasco et al, 2016; Pacifici, 2013). It acts by inhibiting sodium and
chloride reabsorption in the ascending loop of Henle, which in turn increases urine output (Guy,
2011; Comerford, 2016; Pacifici, 2013). It also increases the excretion of potassium, similar to
thiazide diuretics (Comerford, 2016) and decreasing water absorption in the kidneys (Guy,
2011). Furosemide binds exclusively to plasma proteins and bilirubin displacement is negligible
when using normal doses. It enters the tubules by tubular secretion and not filtration. While it
can be used in pediatric patients, the pharmacokinetics are driven by the maturity of the kidneys
(Pacifici, 2013). The long-term use of furosemide is associated with low bone density as a result
of its mechanism of action, which is promotion of calcium wasting (Vasco et al, 2016).

Other loop diuretics include bumetadine, ethacrynic sodium, and torsemide. Like thiazide
diuretics, loop diuretics increase excretion of potassium, although they do produce more diuresis
and electrolyte loss than thiazide diuretics (Vasco et al, 2016). While diuretics are very effective,
they are not without consequence. Side effects include dizziness, weakness, electrolyte
imbalances, hearing loss and tinnitus, hypovolemia, and cardiovascular collapse (Guy, 2011;
Comerford, 2016). When treating heart failure and pulmonary edema, loop diuretics are more
effective than other diuretics (Guy, 2011). However, research has shown that they may escalate
bone metabolic disease (Vasco et al, 2016). Thiazides and thiazide-like diuretics lack these
effects, and research suggests that they can produce a protective effect on bone density (Vasco et
al, 2016). Loop diuretics initially cause vasodilation but often have a latent vasoconstriction
phase as well (Levy and Bellou, 2013). Resistance to loop diuretics has been noted and patients
with resistance typically have poorer outcomes while treating acute heart failure. Patients with
renal failure have been noted to have worsening diagnosis as a result of receiving loop diuretics
(Levy and Bellou, 2013).

Alternatives to Loop Diuretics
Furosemide is very common in the pre-hospital and hospital setting, although there are
other drugs that can be utilized. These include thiazide and thiazide-like diuretics, and
potassium-sparing diuretics. Thiazide and thiazide-like diuretics include HCTZ, indapamide,
metolazone. These drugs “interfere with sodium transport across the tubules of the cortical
diluting segment in the nephron, thereby increasing renal excretion of sodium, chloride, water,
and potassium and decreasing calcium excretion” (Comerford, 2016, p49). These drugs also

exhibit and antihypertensive effect, although the exact mechanism is unknown (Comerford,
2016). Recent studies have indicated that thiazides can exert a renal protective action when in
combination with ACE inhibitors or AT-1 receptor blockers in patients with chronic kidney
disease (Vasco et al, 2016). Loop diuretics have only partially exhibited these effects. Potassiumsparing diuretics include amiloride hydrochloride, spironolactone, triamterene (Comerford,
2016). Spironolactone specifically “inhibits aldosterone at the distal renal tubules, also
promoting sodium excretion and potassium retention” (Comerford, 2016, p48).

Medication Approval Process
The process for medication approval in humans is long and somewhat complex.
According to the FDA, the process begins when an investigational new drug application is
submitted from a sponsor (company, research institution, or other organization) that shows prior
research and testing in animals (2017). A review board consisting of scientists, hospitals, and
research institutions along with the FDA decide if a drug is safe enough to begin human trials
(Review, 2017). The board then develops and approves protocols for testing which include the
type of people that can be included in the trial, schedule of testing and procedures, medication
dosage, the length of study, overall objectives, and many more details (Review, 2017). In
addition to the pre-trial details, the board must also ensure that the patients understand the risks
and do not cause harm to the patients (Review, 2017). The first phase of testing is administered
to a small group of healthy volunteers to determine side effects, metabolism, and excretion
(Review, 2017). The second phase is conducted on patients with a particular disease to determine
its effectiveness against a different drug or placebo (Review, 2017). Next is a large-scale trial,
with several thousand patients (Review, 2017). After clinical trials are complete, the company

can submit a new drug application to the FDA for consideration (Review, 2017). If approved, the
company can begin manufacturing and marketing the new drug to the public (Review, 2017).
Even after the drug is manufactured, it will be continuously studied to determine its effectiveness
and any other side effects it may cause (Review, 2017). Loop diuretics were developed in the
1960s (Pacifici, 2013).

Off-Label Use of Medications
Just because the FDA has approved a drug for a specific purpose does not mean that it
will always be used for it. The companies that approve medications also monitor for off-label use
of the medication, which is the “unapproved use of an approved medication,” according to the
FDA (Label, 2017). This can include use for a condition it is not approved to treat, dispensed in a
different way from its original manufacture, or is given in a different dose (Label, 2017).
However, they do advise consumers to speak with their doctors as they can prescribe it if it is
medically necessary or if they believe that the benefits outweigh the risks (Label, 2017).

Conclusion
Loop diuretics, thiazide and thiazide-like diuretics, and potassium-sparing diuretics are
all useful medications to treat edema in the pre-hospital and hospital settings. Each have their
benefits and risks, which are carefully evaluated by the person administering the medication to
the patient. This evaluation uses the information that is gleaned from clinicals trials carried out
by the FDA and presented to medical personnel to treat their patients who present with edema.
Caution is always used with them as there is always a potential to cause adverse effects to the

patient, even when least expected. The benefit to the patient should always outweigh the risks of
administering a medication to improve out-of-hospital outcomes for the patient.
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